JumpStart Fertility
A platform biotechnology company developing NAD+ technologies to modulate cellular energy, metabolism and ageing biology — with IVF laboratory media as the lead clinical and commercial application.
How the company was formed, and what it is building.
JumpStart Fertility is a platform biotechnology company developing NAD+ (nicotinamide adenine dinucleotide) technologies to modulate cellular energy, metabolism and ageing biology. The lead clinical and commercial application is IVF laboratory media; consumer and animal health streams are also progressing.
The company was founded by Dr Lindsay Wu (Chief Science Officer of Proto Axiom and Head of the Laboratory for Ageing Research at UNSW Sydney). Proto Axiom re‑domiciled JumpStart Fertility to Australia from the United States — all IP and employees now sit within the Australian entity. CEO Dr Stephanie Allen joined to lead commercial strategy, partnerships and capital‑raising.
- Founded
- 2025
- Origin
- UNSW · Re‑domiciled from United States
- Sector
- Therapeutics
- Modality
- NAD+ platform · IVF media
Founders and key team.
Where the programme is now, and what comes next.
- Now
- GMP manufacturing complete. Inbound licensing interest confirmed. Clinic‑based sibling embryo trials in preparation.